Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Daniel Lorber. (2014) Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity 7, pages 169-183.
Read now
Read now
Jennifer B. Green. (2014) Understanding the Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Paradox. Postgraduate Medicine 126:3, pages 190-204.
Read now
Read now
John Gerich. (2013) Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. International Journal of General Medicine 6, pages 877-895.
Read now
Read now
André J. Scheen. (2013) Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes. Postgraduate Medicine 125:3, pages 7-20.
Read now
Read now
Articles from other publishers (7)
Ryeon Heo, Minji Kang, Seo‐Yeong Mun, Minju Park, Eun‐Taek Han, Jin‐Hee Han, Wanjoo Chun, Hongzoo Park, Won‐Kyo Jung, Il‐Whan Choi & Won Sun Park. (2022)
Antidiabetic omarigliptin dilates rabbit aorta by activating voltage‐dependent K
+
channels and the sarco/endoplasmic reticulum Ca
2+
‐ATPase pump
. Fundamental & Clinical Pharmacology 37:1, pages 75-84.
Crossref
Crossref
Hee Seok Jung, Mi Seon Seo, Jin Ryeol An, Ryeon Heo, Minji Kang, Eun-Taek Han, Hongzoo Park, Geehyun Song, Youn Kyoung Son, Won-Kyo Jung, Il-Whan Choi, Sung Hun Na & Won Sun Park. (2021) The anti-diabetic drug alogliptin induces vasorelaxation via activation of Kv channels and SERCA pumps. European Journal of Pharmacology 898, pages 173991.
Crossref
Crossref
Joel Zonszein & Per-Henrik Groop. (2016) Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. Diabetes Therapy 7:4, pages 621-639.
Crossref
Crossref
Tiansheng Wang, Fei Wang, Junwen Zhou, Huilin Tang & Sharon Giovenale. (2016) Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials. Diabetes/Metabolism Research and Reviews 32:8, pages 843-857.
Crossref
Crossref
Liberata Sportiello, Concetta Rafaniello, Cristina Scavone, Cristiana Vitale, Francesco Rossi & Annalisa Capuano. (2016) The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy. International Journal of Cardiology 202, pages 731-735.
Crossref
Crossref
M. D. Sharma. (2015) Potential for combination of dipeptidyl peptidase‐4 inhibitors and sodium‐glucose co‐transporter‐2 inhibitors for the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism 17:7, pages 616-621.
Crossref
Crossref
Antoni Sicras-MainarRuth Navarro-Artieda. (2015) Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients. Diabetes & Metabolism Journal 39:1, pages 74.
Crossref
Crossref